

Michael J HalaÅ¾ka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/504923/publications.pdf>

Version: 2024-02-01

182
papers

7,497
citations

61984

43
h-index

74163

75
g-index

184
all docs

184
docs citations

184
times ranked

10422
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of skeletal muscle density during neoadjuvant chemotherapy in older women with advanced stage ovarian cancer is associated with postoperative complications. <i>European Journal of Surgical Oncology</i> , 2022, 48, 896-902.	1.0	7
2	Fertility-sparing surgery after neo-adjuvant chemotherapy in women with cervical cancer larger than 4 cm: a systematic review. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 486-493.	2.5	3
3	TRP channel expression correlates with the epithelial-mesenchymal transition and high-risk endometrial carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	5.4	9
4	Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions. <i>Cancers</i> , 2022, 14, 1966.	3.7	14
5	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	7.0	26
6	Analysis of awareness and acceptance of SARS-CoV-2 vaccination among pregnant women. <i>Ceska Gynekologie</i> , 2022, 87, 100-103.	0.3	1
7	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. <i>Clinical Chemistry</i> , 2022, 68, 1164-1176.	3.2	6
8	Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1442-1443.	0.6	10
9	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	2.5	12
10	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	5.1	35
11	Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188446.	7.4	41
12	AUTHOR REPLY. <i>Urology</i> , 2021, 151, 127-128.	1.0	0
13	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.	2.0	22
14	Renal and Bladder Cancer During Pregnancy: A Review of 47 Cases and Literature-based Recommendations for Management. <i>Urology</i> , 2021, 151, 118-128.	1.0	4
15	Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy. <i>British Journal of Haematology</i> , 2021, 193, 52-62.	2.5	14
16	Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP). <i>Clinical Pharmacokinetics</i> , 2021, 60, 775-784.	3.5	15
17	The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. <i>Scientific Reports</i> , 2021, 11, 3176.	3.3	17
18	Imaging modalities in pregnant cancer patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 423-431.	2.5	26

#	ARTICLE	IF	CITATIONS
19	Postpartum breast cancer: mechanisms underlying its worse prognosis, treatment implications, and fertility preservation. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 412-422.	2.5	14
20	Cervical cancer in pregnancy at various gestational ages. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 784-788.	2.5	4
21	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. <i>Cancers</i> , 2021, 13, 2040.	3.7	4
22	The MNK1/2-EIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer. <i>Cancer Research</i> , 2021, 81, 3876-3889.	0.9	21
23	Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies. <i>EClinicalMedicine</i> , 2021, 35, 100856.	7.1	42
24	Incorporating molecular profiling into endometrial cancer management requires prospective studies. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 944-945.	2.5	10
25	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. <i>Lancet Oncology</i> , The, 2021, 22, 753-754.	10.7	57
26	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. <i>JAMA Network Open</i> , 2021, 4, e2113180.	5.9	27
27	Twenty years of experience with less radical fertility-sparing surgery in early-stage cervical cancer: Oncological outcomes. <i>Gynecologic Oncology</i> , 2021, 163, 100-104.	1.4	8
28	Wnt/ β -Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 705384.	2.8	17
29	Low preoperative skeletal muscle density is predictive for negative postoperative outcomes in older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 360-367.	1.4	10
30	Non-invasive prenatal testing suggesting a maternal malignancy: What do we tell the prospective parents in Belgium?. <i>Prenatal Diagnosis</i> , 2021, 41, 1264-1272.	2.3	20
31	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. <i>Cancers</i> , 2021, 13, 3988.	3.7	14
32	Placental pathology in cancer during pregnancy and after cancer treatment exposure. <i>Placenta</i> , 2021, 111, 33-46.	1.5	6
33	Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. <i>European Journal of Cancer</i> , 2021, 155, 13-24.	2.8	7
34	Fertility sparing treatment in cervical cancer management in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 75, 101-112.	2.8	4
35	Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo. <i>European Journal of Medicinal Chemistry</i> , 2021, 222, 113562.	5.5	9
36	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	2.2	31

#	ARTICLE	IF	CITATIONS
37	Data describing the poor outcome associated with a breast cancer diagnosis in the post-weaning period. <i>Data in Brief</i> , 2021, 38, 107354.	1.0	2
38	Extracorporeal shock wave therapy for treating dyspareunia: A prospective, randomized, double-blind, placebo-controlled study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2021, 64, 101545.	2.3	3
39	Cancer of the corpus uteri: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 45-60.	2.3	139
40	Immunotherapy for cancer treatment during pregnancy. <i>Lancet Oncology</i> , The, 2021, 22, e550-e561.	10.7	37
41	Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?. <i>Acta Clinica Belgica</i> , 2020, 75, 9-18.	1.2	9
42	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2020, 99, 79-88.	2.8	18
43	Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 335-343.	1.4	10
44	Executive functioning in 6-year old children exposed to chemotherapy in utero. <i>Early Human Development</i> , 2020, 151, 105198.	1.8	7
45	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 538064.	2.8	9
46	The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5409.	4.1	29
47	Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant Populations. <i>Clinical Chemistry</i> , 2020, 66, 1414-1423.	3.2	9
48	Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. <i>PLoS Medicine</i> , 2020, 17, e1003111.	8.4	25
49	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	2.5	21
50	Morcellation of the Uterus: Is There Any Place?. <i>Current Oncology Reports</i> , 2020, 22, 68.	4.0	4
51	Pregnancy and Cancer: the INCIP Project. <i>Current Oncology Reports</i> , 2020, 22, 17.	4.0	72
52	Squamous cell carcinoma with sarcomatoid differentiation or carcinosarcoma of the uterine cervix associated with HPV33 infection: report of a rare case. <i>Diagnostic Pathology</i> , 2020, 15, 12.	2.0	5
53	Atypical Lesions of the Breast and Lobular Carcinoma in Situ in Pregnancy – Surgeons’ Practice. <i>The Journal of Breast Health</i> , 2020, 16, 16-21.	1.0	1
54	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 417-431.	1.6	48

#	ARTICLE	IF	CITATIONS
55	Extracorporeal shock wave therapy for treatment of vulvodynia: a prospective, randomized, double-blind, placebo-controlled study. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 169-174.	2.2	4
56	Pregnant women with confirmed neoplasms should not have noninvasive prenatal testing. <i>Prenatal Diagnosis</i> , 2019, 39, 1162-1165.	2.3	17
57	Long-term impact of prenatal exposure to chemotherapy on executive functioning: An ERP study. <i>Clinical Neurophysiology</i> , 2019, 130, 1655-1664.	1.5	3
58	Noninvasive Prenatal Testing and Detection of Occult Maternal Malignancies. <i>Clinical Chemistry</i> , 2019, 65, 1484-1486.	3.2	19
59	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. <i>Lancet Haematology</i> , 2019, 6, e551-e561.	4.6	45
60	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1073.	2.8	28
61	Age-dependent brain volume and neuropsychological changes after chemotherapy in breast cancer patients. <i>Human Brain Mapping</i> , 2019, 40, 4994-5010.	3.6	25
62	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2019, 154, 531-538.	1.4	49
63	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial " ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	1.4	35
64	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. <i>BMC Cancer</i> , 2019, 19, 506.	2.6	46
65	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4820-4831.	7.0	71
66	Poor outcome in hypoxic endometrial carcinoma is related to vascular density. <i>British Journal of Cancer</i> , 2019, 120, 1037-1044.	6.4	10
67	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 676-682.	2.5	35
68	Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGE survey. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1425-1430.	2.5	4
69	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
70	MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2019, 79, 1646-1657.	0.9	31
71	Development of Patient-Derived Tumor Xenograft Models. <i>Methods in Molecular Biology</i> , 2019, 1862, 217-225.	0.9	12
72	Management of cancer during pregnancy and current evidence of obstetric, neonatal and pediatric outcome: a review article. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 404-416.	2.5	21

#	ARTICLE	IF	CITATIONS
73	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e86.	2.2	18
74	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. <i>Reproductive Sciences</i> , 2018, 25, 1637-1648.	2.5	0
75	Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. <i>Case Reports in Oncology</i> , 2018, 11, 119-124.	0.7	22
76	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. <i>Cancer Medicine</i> , 2018, 7, 1978-1987.	2.8	62
77	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , The, 2018, 19, 337-346.	10.7	235
78	Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study. <i>European Radiology</i> , 2018, 28, 1862-1874.	4.5	46
79	Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. <i>Modern Pathology</i> , 2018, 31, 816-828.	5.5	46
80	Fertility preservation healthcare circuit and networks in cancer patients worldwide: what are the issues?. <i>BMC Cancer</i> , 2018, 18, 192.	2.6	15
81	Recovery from chemotherapy-induced white matter changes in young breast cancer survivors?. <i>Brain Imaging and Behavior</i> , 2018, 12, 64-77.	2.1	52
82	Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. <i>International Journal of Cancer</i> , 2018, 142, 1230-1243.	5.1	59
83	Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. <i>Laryngoscope</i> , 2018, 128, 1493-1500.	2.0	17
84	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
85	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 37-50.	2.3	290
86	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. <i>Vaccines</i> , 2018, 6, 56.	4.4	7
87	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	12.8	178
88	Modeling Endometrial Cancer: Past, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2348.	4.1	82
89	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. <i>Frontiers in Nutrition</i> , 2018, 5, 138.	3.7	32
90	2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of the head and neck. <i>Oncotarget</i> , 2018, 9, 28572-28585.	1.8	6

#	ARTICLE	IF	CITATIONS
91	Implementation of cancer treatment during pregnancy in daily practice: the important role of perinatologists. <i>Oncotarget</i> , 2018, 9, 31795-31796.	1.8	2
92	Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomasâ€”an ENITEC Group Initiative. <i>Clinical Cancer Research</i> , 2017, 23, 1274-1285.	7.0	30
93	Integration and validation of the ex vivo human placenta perfusion model. <i>Journal of Pharmacological and Toxicological Methods</i> , 2017, 88, 25-31.	0.7	34
94	Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. <i>Development (Cambridge)</i> , 2017, 144, 1775-1786.	2.5	228
95	European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 189-192.	2.5	45
96	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. <i>Gynecologic Oncology</i> , 2017, 146, 538-545.	1.4	16
97	Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. <i>Journal of Pathology</i> , 2017, 242, 24-38.	4.5	54
98	Effects of cancer treatment during pregnancy on fetal and child development. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 302-310.	5.6	48
99	Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 7232-7241.	7.0	37
100	Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. <i>European Journal of Cancer</i> , 2017, 83, 88-98.	2.8	93
101	Low-grade bronchial mucoepidermoid carcinoma during pregnancy successfully treated by lobectomy. <i>Journal of Obstetrics and Gynaecology</i> , 2017, 37, 1082-1084.	0.9	0
102	Comment on â€œMaternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature reviewâ€” <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 261-262.	1.1	5
103	Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. <i>Clinical Cancer Research</i> , 2017, 23, 2223-2231.	7.0	80
104	Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 61-67.	2.5	9
105	Ovarian cancer in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 108-117.	2.8	41
106	Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners. <i>Psycho-Oncology</i> , 2017, 26, 1215-1221.	2.3	31
107	Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. <i>PLoS ONE</i> , 2017, 12, e0182223.	2.5	7
108	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1525.	4.1	3

#	ARTICLE	IF	CITATIONS
109	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over	0.9	5
110	External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 142, 83-88.	1.4	4
111	Characteristics and prognosis of patients with early-stage endometrial cancer who refuse adjuvant radiotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 428-433.	1.4	8
112	Evaluation of models to predict lymph node metastasis in endometrial cancer: A multicentre study. <i>European Journal of Cancer</i> , 2016, 61, 52-60.	2.8	27
113	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	21.4	77
114	Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. <i>British Journal of Radiology</i> , 2016, 89, 20160468.	2.2	18
115	Recurrent <i>PPP2R1A</i> Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth. <i>Cancer Research</i> , 2016, 76, 5719-5731.	0.9	89
116	Long-term oncological safety of minimally invasive surgery in high-risk endometrial cancer. <i>European Journal of Cancer</i> , 2016, 65, 185-191.	2.8	35
117	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	2.5	64
118	Tumour hypoxia causes DNA hypermethylation by reducing TET activity. <i>Nature</i> , 2016, 537, 63-68.	27.8	521
119	Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study. <i>Endoscopy</i> , 2016, 48, 1016-1022.	1.8	10
120	Treatment of gynecological cancers diagnosed during pregnancy. <i>Future Oncology</i> , 2016, 12, 2265-2275.	2.4	2
121	A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 319-330.	2.5	25
122	Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. <i>Lancet Oncology</i> , The, 2016, 17, 273-274.	10.7	9
123	Effects of prenatal exposure to cancer treatment on neurocognitive development, a review. <i>NeuroToxicology</i> , 2016, 54, 11-21.	3.0	6
124	Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines. <i>Oncotarget</i> , 2016, 7, 46120-46126.	1.8	29
125	Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. <i>Anticancer Research</i> , 2016, 36, 5381-5384.	1.1	6
126	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. <i>Scientific Reports</i> , 2015, 5, 17369.	3.3	35

#	ARTICLE	IF	CITATIONS
127	Potential Therapeutic Targets in Uterine Sarcomas. <i>Sarcoma</i> , 2015, 2015, 1-14.	1.3	34
128	Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. <i>Sarcoma</i> , 2015, 2015, 1-14.	1.3	22
129	Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. <i>JAMA Oncology</i> , 2015, 1, 814.	7.1	180
130	Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging. <i>Gynecologic Oncology</i> , 2015, 138, 299-303.	1.4	50
131	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S96-104.	2.3	70
132	ESMOĀ€ESGOĀ€ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 559-581.	0.6	167
133	Contraception is as important as fertility preservation in young women with cancer. <i>Lancet</i> , The, 2015, 385, 508.	13.7	11
134	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. <i>Lancet Haematology</i> , the, 2015, 2, e55-e65.	4.6	115
135	Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed childrenĀwith nonexposed controls. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 830-831.	1.3	2
136	Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. <i>Gynecologic Oncology</i> , 2015, 139, 118-126.	1.4	52
137	Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. <i>Gynecologic Oncology</i> , 2015, 138, 165-173.	1.4	26
138	Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. <i>Modern Pathology</i> , 2015, 28, 1001-1010.	5.5	60
139	Staging for endometrial cancer: The controversy around lymphadenectomy Ā€ Can this be resolved?. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 845-857.	2.8	30
140	Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 2.	2.4	33
141	Management of cancer in pregnancy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2015, 29, 741-753.	2.8	63
142	Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. <i>New England Journal of Medicine</i> , 2015, 373, 1824-1834.	27.0	283
143	Morcellation of uterine leiomyomas: a plea for patient triage. <i>Lancet Oncology</i> , The, 2015, 16, 1454-1456.	10.7	22
144	The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. <i>Gynecologic Oncology</i> , 2015, 138, 378-382.	1.4	5

#	ARTICLE	IF	CITATIONS
145	Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group. <i>Gynecologic Oncology</i> , 2015, 138, 278-284.	1.4	19
146	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	2.9	50
147	Spontaneous Post-Transplant Disorders in NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. <i>PLoS ONE</i> , 2015, 10, e0124974.	2.5	23
148	Prospective Randomized Study of <sc>MiniArc</sc> and Ajust Single Incision Sling Procedures. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 172-174.	1.3	8
149	Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 415-422.	1.4	38
150	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S67-S72.	2.5	75
151	Primary brain tumours, meningiomas and brain metastases in pregnancy: Report on 27 cases and review of literature. <i>European Journal of Cancer</i> , 2014, 50, 1462-1471.	2.8	54
152	The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. <i>Journal of Clinical Virology</i> , 2014, 59, 18-23.	3.1	39
153	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. <i>Human Pathology</i> , 2014, 45, 522-532.	2.0	36
154	Strategies for fertility preservation in young early breast cancer patients. <i>Breast</i> , 2014, 23, 503-510.	2.2	42
155	Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?. <i>Gynecologic Oncology</i> , 2013, 128, 6-11.	1.4	105
156	The âœLeuvenâœpaclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study. <i>Gynecologic Oncology</i> , 2013, 128, 34-37.	1.4	9
157	Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2532-2539.	1.6	261
158	Chemotherapy during pregnancy. <i>Current Opinion in Oncology</i> , 2012, 24, 580-586.	2.4	39
159	Cancer of the corpus uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 119, S110-7.	2.3	149
160	Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. <i>BMC Medicine</i> , 2012, 10, 86.	5.5	103
161	Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. <i>Anticancer Research</i> , 2011, 31, 2367-71.	1.1	18
162	Reply to H.A. Azim Jr et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e304-e304.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Revised FIGO staging for endometrial cancer. Southern African Journal of Gynaecological Oncology, 2010, 2, 40-41.	0.3	0
164	High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. Journal of Medical Case Reports, 2010, 4, 243.	0.8	8
165	Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study. Breast Journal, 2009, 15, 461-467.	1.0	79
166	Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature. International Journal of Gynecological Cancer, 2009, 19, 245-248.	2.5	20
167	Gynecologic oncology in pregnancy. Critical Reviews in Oncology/Hematology, 2008, 67, 187-195.	4.4	26
168	Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecologic Oncology, 2006, 103, 1137-1140.	1.4	45
169	Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecologic Oncology, 2005, 98, 274-280.	1.4	142
170	Chemotherapy for cervical cancer. European Clinics in Obstetrics and Gynaecology, 2005, 1, 143-150.	0.4	2
171	Different Subtypes of Uterine Sarcoma Require a Separate Therapeutic Approach. Women's Health, 2005, 1, 375-383.	1.5	0
172	A possible role of the cytochrome P450c17 α gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetrica Et Gynecologica Scandinavica, 2004, 83, 234-239.	2.8	12
173	Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenocarcinoma. Gynecologic Oncology, 2004, 93, 680-685.	1.4	58
174	ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecologic Oncology, 2004, 95, 583-587.	1.4	54
175	A possible role of the cytochrome P450c17 α gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: a pilot study. Acta Obstetrica Et Gynecologica Scandinavica, 2004, 83, 234-9.	2.8	21
176	Endometrial stromal sarcoma with a sole t(X;17) chromosome change: report of a case and review of the literature. Gynecologic Oncology, 2003, 88, 459-462.	1.4	24
177	The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecologic Oncology, 2003, 90, 37-43.	1.4	71
178	Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecologic Oncology, 2003, 90, 372-377.	1.4	34
179	2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth. Gynecologic Oncology, 2003, 91, 299-308.	1.4	12
180	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. Journal of the Society for Gynecologic Investigation, 2003, 10, 105-109.	1.7	16

#	ARTICLE	IF	CITATIONS
181	Cumulative dosage effect of aRAD5111/HMGA2 fusion and RAD5111 loss in a case of pseudo-Meigs' syndrome. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 324-329.	2.8	12
182	The misoprostal third stage study: a randomised controlled comparison between orally administered misoprostol and standard management A double-blind placebo controlled randomised trial of misoprostol and oxytocin in the management of the third stage labour. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2001, 108, 338-338.	2.3	7